Where should enzalutamide be in the metastatic Castration Resistant Prostate Cancer (mCRPC): A multi-center study

Basit Öğe Kaydı
dc.authorid0000-0002-8370-1587en_US
dc.authorid0000-0003-2360-3392en_US
dc.authorid0000-0002-1171-8320en_US
dc.authorid0000-0001-6535-6030en_US
dc.authorid0000-0002-6291-7573en_US
dc.authorid0000-0003-4533-0620en_US
dc.authorid0000-0002-7931-2941en_US
dc.contributor.authorKoca, Sinan
dc.contributor.authorÖkten, İlker Nihat
dc.contributor.authorBeşiroğlu, Mehmet
dc.contributor.authorTelli, Tuğba Akın
dc.contributor.authorDemirci, Ayşe
dc.contributor.authorKaraağaç, Mustafa
dc.contributor.authorOruç, Zeynep
dc.date.accessioned2023-08-10T13:10:47Z
dc.date.available2023-08-10T13:10:47Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.description.abstractObjectives: Enzalutamide(ENZ) is an effective hormonal treatment modality in mCRPC. It can be used before or after docetaxel(DTX) in this setting. Herein, we aimed to show the efficacy of ENZ before or after DTX use and the factors predicting the efficacy. Methods: We retrospectively collected the data of 320 patients from 12 centers who were treated with ENZ in mCRPC. The initial stage, age, line of treatment, serum prostate-specific antigen (PSA) levels before ENZ treatment and at nadir, site of metastasis, gleason score were evaluated. Results: Median age of 320 patients were 69. At a median follow-up of 56 months, 271/320 (84.7%) disease progression and 230/320(71.9%) death had been observed. Median PFS was 11(8.9-13)) and median OS was 25(22.1-27.8) months in all patients group. Median PFS was 10(7.4-12.5) months, 11(8-13.9) months in pre-DTX and post-DTX groups respectively. Median OS was higher in the post-DTX group than the pre-DTX group (28(25.7-30.2) vs 19(15.0-22.9-46.6) (p:0.000). Gleason score≥8 (HR 0.59, 95%CI 0.46-0.77, p=0.00), presence of non-visceral metastasis (HR 0.72, 95%CI 0.53-0.97, p=0.031), initial PSA value<43(median) (HR 0.70, 95%CI 0.54-0.91, p=0.009), PSA at nadir <2 (HR 0.61, 95%CI 0.44-0.85, p=0.004), >50% decline in PSA (HR 0.27, 95%CI 0.19-0.36, p=0.000) significantly predicted ENZ response regarding rPFS. Conclusion: ENZ has shown equal efficacy before and after DTX treatment in mCRPC regarding rPFS. But OS rate was significantly better in the pre-DTX group. Therefore, we recommend starting with DTX in patients who can tolerate chemotherapy in mCRPC setting.en_US
dc.identifier.citationKoca, S., Ökten, İ. N., Beşiroğlu, M., Telli, T. A., Demirci, A., Karaağaç, M. ve diğerleri. (2023). Where should enzalutamide be in the metastatic Castration Resistant Prostate Cancer (mCRPC): A multi-center study. Eurasian Journal of Medicine and Oncology, 7(1), 34-41.en_US
dc.identifier.doi10.14744/ejmo.2023.69719
dc.identifier.endpage41en_US
dc.identifier.issn2587-2400
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85150276763
dc.identifier.scopusqualityQ2
dc.identifier.startpage34en_US
dc.identifier.trdizinid1166457
dc.identifier.urihttps://www.ejmo.org/10.14744/ejmo.2023.69719/
dc.identifier.urihttps://hdl.handle.net/11468/12472
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1166457
dc.identifier.volume7en_US
dc.identifier.wosWOS:001135809500007
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorOruç, Zeynep
dc.language.isoenen_US
dc.publisherKare Publishingen_US
dc.relation.ispartofEurasian Journal of Medicine and Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectProstate canceren_US
dc.subjectEnzalutamideen_US
dc.subjectDocetaxelen_US
dc.subjectLine of treatmenten_US
dc.titleWhere should enzalutamide be in the metastatic Castration Resistant Prostate Cancer (mCRPC): A multi-center studyen_US
dc.titleWhere should enzalutamide be in the metastatic Castration Resistant Prostate Cancer (mCRPC): A multi-center study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Where Should Enzalutamide Be in The Metastatic Castration.pdf
Boyut:
537.59 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu